A retrospective study in multiple sclerosis patients evaluating effect of Dimethyl Fumarate on absolute lymphocyte count.

Trial Profile

A retrospective study in multiple sclerosis patients evaluating effect of Dimethyl Fumarate on absolute lymphocyte count.

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Dimethyl fumarate (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Nov 2016 New trial record
    • 17 Sep 2016 Results assessing safety presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top